BKPyV | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

10 results for “BKPyV”

Trials

Not yet recruiting

Study of Anti-BKPyV Immune Responses in Kidney Transplant Patients With BKPyV Viremia

75 participants · First posted May 23, 2025

A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients

280 participants · First posted Apr 13, 2022

Drugs

Monoclonal antibody (first-in-class therapeutic antibody)

Potravitug

Manufacturer: Memo Therapeutics AG

Conditions: BK polyomavirus infection, BKPyV nephropathy (BKPyVAN)

News

Potravitug Demonstrates Statistically Significant Viral Clearance in Phase II BK Polyomavirus Trial, Paving Way for Pivotal Phase III

Memo Therapeutics Publishes First Study Mapping BK Polyomavirus Impact on Kidney Transplant Recipients' Quality of Life

Memo Therapeutics' Potravitug Receives EU Orphan Designation for BK Polyomavirus Infection in Kidney Transplant Patients